Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ691MR)

This product GTTS-WQ691MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ691MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12387MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ12828MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ7445MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ1138MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ12315MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ918MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ4475MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ10975MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW